TTVR STRONG Under Coverage With Evidence Development (CED) Study

Recruiting now

Conditions studied: Tricuspid Regurgitation

In brief

This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.

Key facts

Study ID

NCT06833476

Run by

Edwards Lifesciences

People needed

2044

Starts

2025-03-19

Expected to finish

2032-12-31

Last updated by the study team

2025-03-28

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Medicare eligible patients who have received an EVOQUE device or are EVOQUE eligible and have at least severe Tricuspid Regurgitation

You may not qualify if…

• Commercially insured patients who have received an EVOQUE device or are EVOQUE eligible or Medicare eligible patients with less than severe Tricuspid Regurgitation

Where it is running

• Edwards Lifesciences — Irvine, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.